Blood brain barrier permeability increases with age in individuals with 22q11.2 deletion syndrome

Abstract

 

22q11.2 deletion syndrome (22q11.2DS) is characterised by high rates of psychotic disorders and immune abnormalities. Blood–brain barrier (BBB) permeability is known to be a risk factor for schizophrenia and immune aberrations.

Objective

To evaluate the relationship between psychosis and BBB permeability in this population.

Methods

We examined two biomarkers for BBB permeability, s100β and neuron-specific enolase (NSE), in 22q11.2DS individuals with/without psychosis. The first cohort of this Israeli–Belgium study was comprised of 20 22q11.2DS adults (30.58 ± 9.42 years) afflicted with a psychotic disorder, another group of 69 non-psychotic 22q11.2DS adults (23.42 ± 8.36 years), and 58 healthy controls (26.39 ± 7.77 years). A second cohort was comprised of 18 non-psychotic 22q11.2DS Israeli children (5.83 ± 1.55 years) and 14 healthy controls (5.34 ± 1.43 years). NSE and s100β serum levels were detected in all participants.

Results

Both factors were elevated in adults with 22q11.2DS compared to healthy controls, specifically in the non-psychotic sub-group. In contrast, there were no significant differences in their levels between the two groups of the paediatric cohort.

Conclusions

Increased BBB permeability seems to be a trait of 22q11.2DS that evolves sometime in early adulthood. Our findings are in line with previous reports on non-syndromic schizophrenia, and suggest potential novel neural pathways to psychosis in 22q11.2DS.

Keywords:

• 22q11.2DS
• blood–brain barrier (BBB)
• psychosis
• s100β
• neuron-specific enolase (NSE)

Acknowledgements

None.

Disclosure statement

None to declare.

Additional information

Funding

This study was financially supported by the National Institute for Psychobiology in Israel Young Investigator’s grant to Drs. Michal Taler and Ehud Mekori–Domachevsky and by the Binational Science Foundation [2017369].